---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-027540"
form_type: "8-K"
ticker: "ICCC"
cik: "0000811641"
company_name: "IMMUCELL CORP /DE/"
filed_at: "2023-04-05T23:59:59+00:00"
generated_at: "2026-06-17T06:09:46.087230+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ImmuCell Q1 2023 sales $3.45M, down 43% YoY; backlog rises to $7.5M

## Summary
- Q1 2023 sales $3.45M vs $6.00M in Q1 2022, a 43% decrease due to production slowdown from contamination events.
- Trailing twelve months sales $16.01M vs $21.14M, down 24%.
- Backlog of orders increased to $7.5M as of March 31, 2023, from $2.5M at Dec 31, 2022.
- Quality control improvements: first test pass rate 82%, subsequent tests 100% success; production ramping up in Q2.
- Expects third submission of CMC Technical Section for Re-Tain FDA approval around end of April 2023, subject to six-month review.

## SEC filing metadata
- accession: 0001213900-23-027540
- form_type: 8-K
- ticker: ICCC
- cik: 0000811641
- company_name: IMMUCELL CORP /DE/
- filed_at: 2023-04-05T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/811641/000121390023027540/0001213900-23-027540-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/811641/000121390023027540/ea176604-8k_immucell.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-027540
- JSON: https://secwatch.observer/filing/0001213900-23-027540.json
- Plain text: https://secwatch.observer/filing/0001213900-23-027540.txt

## Key facts
- Earnings Releases
  IMMUCELL CORP /DE/ reported the first quarter of 2023, which ended March 31, 2023 results: revenue $3.45 million.
  - Period: the first quarter of 2023, which ended March 31, 2023
  - Revenue: $3.45 million
  - Result: preliminary results
  source text: unaudited sales results for the first quarter of 2023, which ended March 31, 2023. 2023 2022 ($ Decrease) (% Decrease) During the Three-Month Periods Ended March 31, $3.45 million $6.00 million ($2.55 million) (43 )% During the Twelve-Month Periods Ended March 31, $16.01 million $21.14 million ($5.12 million) (24 )% Actual sales during the first quarter of
  evidence_url: https://www.sec.gov/Archives/edgar/data/811641/000121390023027540/0001213900-23-027540-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.